id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-289115-bntcn0m6	Thangaraju, Pugazhenthan	Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis	2020-09-10		.txt	text/plain	2136	110	49	There are isolated case reports and series that document a milder course of COVID-19 infection in patients who have already been on dupilumab therapy for treatment of conditions such as atopic dermatitis and chronic rhino-sinusitis with nasal polyp. While it has already been in use in dermatology clinics for the treatment of atopic dermatitis (AD), it was most recently approved for the indication of chronic rhinosinusitis with nasal polyp (CRSwNP) by the US Food and Drug Association (FDA) on the 26th of June, 2019 [1] . We included clinical trials, research studies, case reports, and randomized control trials that employed the use of dupilumab at any point in the treatment of patients who were laboratory confirmed cases of COVID19. Details that were extracted included author and journal details, year of publication, sample size, age, sex, indication for rational use of dupilumab, duration for treatment, adverse effects observed, and course of COVID-19 infection. COVID-19 infection in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab	./cache/cord-289115-bntcn0m6.txt	./txt/cord-289115-bntcn0m6.txt